Silvia Lee1, Patricia P Wadowski1, Timothy Hoberstorfer1, Constantin Weikert1, Joseph Pultar1, Christoph W Kopp1, Simon Panzer2, Thomas Gremmel3,4. 1. Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. 2. Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria. 3. Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. thomas.gremmel@meduniwien.ac.at. 4. Department of Internal Medicine I, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria. thomas.gremmel@meduniwien.ac.at.
Abstract
PURPOSE: Hyperuricemia carries an increased risk of atherothrombotic events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). This may at least in part be due to inadequate P2Y12 inhibition. The aim of this study was to prospectively investigate the potential association between hyperuricemia and decreased platelet inhibition by P2Y12 antagonists. METHODS: Levels of uric acid as well as on-treatment residual platelet reactivity in response to adenosine diphosphate (ADP) were assessed in 301 clopidogrel-treated patients undergoing elective angioplasty and stenting, and in 206 prasugrel- (n = 118) or ticagrelor-treated (n = 88) ACS patients following acute PCI. Cut-off values for high on-treatment residual ADP-inducible platelet reactivity (HRPR) were based on previous studies showing an association of test results with clinical outcomes. RESULTS: Hyperuricemia was significantly associated with increased on-treatment residual ADP-inducible platelet reactivity in clopidogrel- and prasugrel-treated patients in univariate analyses and after adjustment for differences in patient characteristics by multivariate regression analyses. In contrast, ticagrelor-treated patients without and with hyperuricemia showed similar levels of on-treatment residual platelet reactivity to ADP. HRPR occurred more frequently in clopidogrel- and prasugrel-treated patients with hyperuricemia than in those with normal uric acid levels. In contrast, hyperuricemic patients receiving ticagrelor did not have a higher risk of HRPR compared with those with normal uric acid levels. CONCLUSION: Hyperuricemia is associated with decreased platelet inhibition by thienopyridines but a normal response to ticagrelor. It remains to be established if lowering uric acid increases the antiplatelet effects of clopidogrel and prasugrel in hyperuricemic patients with HRPR.
PURPOSE: Hyperuricemia carries an increased risk of atherothrombotic events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). This may at least in part be due to inadequate P2Y12 inhibition. The aim of this study was to prospectively investigate the potential association between hyperuricemia and decreased platelet inhibition by P2Y12 antagonists. METHODS: Levels of uric acid as well as on-treatment residual platelet reactivity in response to adenosine diphosphate (ADP) were assessed in 301 clopidogrel-treated patients undergoing elective angioplasty and stenting, and in 206 prasugrel- (n = 118) or ticagrelor-treated (n = 88) ACS patients following acute PCI. Cut-off values for high on-treatment residual ADP-inducible platelet reactivity (HRPR) were based on previous studies showing an association of test results with clinical outcomes. RESULTS: Hyperuricemia was significantly associated with increased on-treatment residual ADP-inducible platelet reactivity in clopidogrel- and prasugrel-treated patients in univariate analyses and after adjustment for differences in patient characteristics by multivariate regression analyses. In contrast, ticagrelor-treated patients without and with hyperuricemia showed similar levels of on-treatment residual platelet reactivity to ADP. HRPR occurred more frequently in clopidogrel- and prasugrel-treated patients with hyperuricemia than in those with normal uric acid levels. In contrast, hyperuricemic patients receiving ticagrelor did not have a higher risk of HRPR compared with those with normal uric acid levels. CONCLUSION: Hyperuricemia is associated with decreased platelet inhibition by thienopyridines but a normal response to ticagrelor. It remains to be established if lowering uric acid increases the antiplatelet effects of clopidogrel and prasugrel in hyperuricemic patients with HRPR.
Authors: Thomas Gremmel; Cihan Ay; Julia Riedl; Christoph W Kopp; Beate Eichelberger; Renate Koppensteiner; Simon Panzer Journal: Thromb Haemost Date: 2015-10-15 Impact factor: 5.249
Authors: Laurent Bonello; Udaya S Tantry; Rossella Marcucci; Ruediger Blindt; Dominick J Angiolillo; Richard Becker; Deepak L Bhatt; Marco Cattaneo; Jean Philippe Collet; Thomas Cuisset; Christian Gachet; Gilles Montalescot; Lisa K Jennings; Dean Kereiakes; Dirk Sibbing; Dietmar Trenk; Jochem W Van Werkum; Franck Paganelli; Matthew J Price; Ron Waksman; Paul A Gurbel Journal: J Am Coll Cardiol Date: 2010-09-14 Impact factor: 24.094
Authors: F Leyva; S D Anker; I F Godsland; M Teixeira; P G Hellewell; W J Kox; P A Poole-Wilson; A J Coats Journal: Eur Heart J Date: 1998-12 Impact factor: 29.983
Authors: Laura G Sánchez-Lozada; Virgilia Soto; Edilia Tapia; Carmen Avila-Casado; Yuri Y Sautin; Takahiko Nakagawa; Martha Franco; Bernardo Rodríguez-Iturbe; Richard J Johnson Journal: Am J Physiol Renal Physiol Date: 2008-08-13
Authors: Patricia P Wadowski; Constantin Weikert; Joseph Pultar; Silvia Lee; Beate Eichelberger; Renate Koppensteiner; Irene M Lang; Simon Panzer; Thomas Gremmel Journal: Cardiovasc Drugs Ther Date: 2020-02-15 Impact factor: 3.727